-

Gilead Provides Additional Information Regarding 2020 Annual Meeting of Stockholders Due to COVID-19 Precautions

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that due to the COVID-19 pandemic and to support the health and safety of the company’s stockholders, employees, Board of Directors and surrounding communities, Gilead’s 2020 Annual Meeting of Stockholders will be held in a virtual-only format instead of as an in-person meeting. In light of this change, stockholders will not be able to attend the Annual Meeting in person.

The Annual Meeting will be held Wednesday, May 6, 2020 at 10:00 a.m. Pacific Daylight Time, as previously scheduled. As described in the proxy materials for the Annual Meeting, holders of our common stock at the close of business on March 13, 2020, the record date, are entitled to participate in the Annual Meeting. To participate on the day of the meeting, stockholders will need to go to east.virtualshareholdermeeting.com/GILD2020 and log in using the 16-digit control number found on their proxy card, voting instruction form or notice of internet availability.

Additional information about how to participate in the Annual Meeting will be available on our Investors page at http://investors.gilead.com/annual-meeting.

About Gilead Sciences

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.

For more information about Gilead, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@Gilead Sciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

Contacts

Douglas Maffei, PhD, Investors
(650) 522-2739

Chris Ridley, Media
(650) 235-2220

Industry:

Gilead Sciences, Inc.

NASDAQ:GILD
Release Versions
English

Contacts

Douglas Maffei, PhD, Investors
(650) 522-2739

Chris Ridley, Media
(650) 235-2220

More News From Gilead Sciences, Inc.

Positive Phase 3 IDEAL Study Results Further Support Livdelzi®’s (Seladelpar) Impact on Achieving ALP Normalization Goals in Second-Line Treatment Across a Broad Population of People Living with Primary Biliary Cholangitis (PBC)

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the detailed results from the Phase 3 IDEAL study, which demonstrated that the majority of participants living with PBC and treated with Livdelzi® (seladelpar) achieved the alkaline phosphatase (ALP) normalization composite endpoint defined as a composite of ALP ≤ 1.0× upper limit of normal (ULN) and a ≥ 15% decrease from baseline. ALP is a key marker of disease activity and long-term outcomes in PBC. The...

Gilead and Kite Advance Leadership With New Data Across Pipeline and Portfolio at ASH 2026

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, today announced 23 presentations, including 7 oral presentations, will be presented at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition (December 12–15, 2026). These latest clinical milestones demonstrate transformative progress across Gilead and Kite’s pipeline and portfolio, from new data for the investigational anitocabtagene autoleucel (anito-cel) in relapsed or...

Gilead to Present Late-Breaking Clinical Data and Real-World Evidence at HIV Glasgow

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced its upcoming participation in the International Congress on Drug Therapy in HIV Infection (HIV Glasgow 2026), taking place from November 8-11. As a leader in HIV innovation, Gilead will share new clinical data and real-world evidence from its HIV research and development programs and provide updates on its strategic initiatives and key collaborations. Results from more than 50 studies, including late-brea...
Back to Newsroom